Ardelyx: Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.Title: Safety and Tolerability of Tenapanor in Pediatric Patients With Irritable Bowel Syndrome With Constipation: An Analysis of Blinded Safety Data from a Phase 3 Study and its Open-Label ExtensionAuthors: Thomas Wallach, Mihaela Ringheanu, Ana Roig Cantisano, Yang Yang, Karishma Raju, Jocelyn Tabora, Susan EdelsteinPoster Number: Sa1643Date/Time: May 3, 2025, from 12:30 PM to 1:30 PM PDTTitle: Neither Tenapanor nor its Major Metabolite Were Detected in the Breast Milk of Healthy Lactating Females After 4 Days of Dosing: A Phase 1, Open-Label, Pharmacokinetic StudyAuthors: Darren Brenner, Karishma Raju, Kenji Kozuka,Yang Yang, Suling Zhao, Susan EdelsteinPoster Number: Sa1673Date/Time: May 3, 2025, from 12:30 PM to 1:30 PM PDTTitle: Patient-Reported IBS-C Symptom Severity Correlates Positively With Financial Burden: Results From the IBS in America 2024 Real-World SurveyAuthors: Eric Shah, Luisa Scott, Johannah Ruddy, Elizabeth Stremke, Laura Williams, Baharak MoshireePoster Number: Mo1257Date/Time: May 5, 2025, from 12:30 PM to 1:30 PM PDTIn addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: "Integrating a Different Mechanism of Action, a different Class of Therapy, Into the Treatment of Adults with IBS-C," on May 4, 2025, from 12:50-1:35 PM PDT, where Satish Rao, MD, and Christina Hanson, NP, will ...Full story available on Benzinga.com